Signpath pharma
WebSignPath Pharma Inc. Raises $235k in Series A led by Undisclosed Investor. Investment . 12/8/17 . $235K . SEC Form D. launch Source. SignPath Pharma Inc. Raises $245k in Series A from Undisclosed Investor. Investment . 7/15/16 . $245K . SEC form D. launch Source. SignPath Pharma Inc. Raises $2.4M in Series A from Undisclosed Investor. WebSignPath Pharma Inc. Quarterly Report on Form 10-Q. Period Ended March 10, 2010 . Table of Contents . Page. PART I . FINANCIAL INFORMATION . Item 1. Financial Statements: Condensed Balance Sheets as of March 31, 2010 (unaudited) and December 31, …
Signpath pharma
Did you know?
WebSignpath Pharma Inc 2014-11-21 Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders 19 US20150072012A1 US Application Laila Pharmaceuticals Pvt Ltd (India). 2014-11-13 Novel highly bioavailable, water soluble and sustained release nanoformulations hydrophobic plant derived compounds and extracts WebOur core product candidate, STP705, is a dual TGF-ß1/COX-2 inhibitor. TGF-ß1 and COX-2 are well-validated gatekeeper targets for oncology and fibrosis disease drug development.
WebSignPath Pharma. Manufacturing · Pennsylvania, United States · <25 Employees . SignPath Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development … WebJun 26, 2024 · Applicants: Board of Regents, The University of Texas System, SignPath Pharma Inc. Inventors: Razelle Kurzrock, Lan Li, Kapil Mehta, Bharat Bhushan Aggarawal, Lawrence Helson LIPOSOMAL MITIGATION OF DRUG-INDUCED LONG QT SYNDROME AND POTASSIUM DELAYED-RECTIFIER CURRENT. Publication number: 20140242156 ...
WebAug 9, 2010 · SignPath Pharma has provided partial support for these studies through offsetting the costs of polymer synthesis. S. Bisht, G. Feldman, and An. Maitra have filed a patent application (U.S. 2008/0107749) that is relevant to the formulation described in … WebSignpath Pharma Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) 2024-04-09 Filing date …
WebSignpath Pharma General Information. Description. Operator of a drug development platform intended to eliminate the cardiac side effects of the drugs. The company is involved in developing products to treat cancer while mitigating drug-induced cardiac arrhythmia and cardiac damage, enabling its customers to receive chemotherapy without …
WebSignpath Pharma is a clinical-stage company with a drug development platform that creates heart-safe drugs. It is based in Sandy, Utah. Headquarters Location. 7984 South 1300 East . Sandy, Utah, 84094, United States. Suggest an edit. Missing: Signpath Pharma's Product Demo & Case Studies. how does medicare reimburse providersWebNov 4, 2024 · SignPath Pharma Inc. announced the commercial out-license of its proprietary CorreQT technology platform. SignPath entered into an agreement with Rain … how does medication errors affect nursesWebOct 31, 2024 · SignPath Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of heart safe drugs for the treatment of serious diseases. The first such drug, LipoCurc TM, an anti-cancer compound, has successfully completed Phase I … photo of fetus at 6 weeksWebSignpath Pharma is headquartered in Sandy, Utah (a suburb of Salt Lake City.) We have partnerships and working relationships with labs, hospitals, and other companies in … Kai Larson joined Signpath Pharma in May of 2015 as VP, Business Development, … Signpath is working on compound optimization for this cancer supportive … Signpath Pharma, Inc. 7984 South 1300 East Sandy, UT 84094 . OUTSIDE … how does medicare work if still employedWebSignPath Pharma Inc operates as a biotechnology company. The Company researches curcumin, a compound that occurs in the tumeric plant, as a treatment for malignant diseases. SignPath researches ... how does medicare set aside workWebApr 27, 2024 · On March 17, 2024, SignPath Pharma issued a press release stating its intention to pursue a therapeutic treatment for COVID-19 with SignPath’s proprie. On … photo of fieldfareWebAcepodia’s gamma delta (γδ)2 T cell program harnesses the unique properties of γδ2 T cells to develop a new class of off-the-shelf allogeneic cell therapies for the treatment of cancer. γδ2 T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies. how does medication affect oral health